Navigation Links
HumanZyme® Announces Human Cell-Expressed Interferon beta for Immunology and Immunotherapy Research Applications
Date:8/8/2017

HumanZyme Inc., a leading supplier of novel recombinant human proteins and growth factors expressed in human cells, today announced the launch of HumanKine® Interferon beta (IFN beta) expressed from HEK293 cells. IFN beta is a member of the type I family of interferons that activate Th1-type innate immune responses against viral and bacterial infection, and have antiproliferative and immunomodulatory functions. IFN beta is currently FDA-approved in injectable form as a treatment for multiple sclerosis, an autoimmune disease, and has been investigated for use in cancer therapeutics for its anti-tumor activity.

According to Scott Coleridge, CEO at HumanZyme, “We are proud to be the only commercial supplier of high-quality, tag-free recombinant human Interferon beta expressed in human cells for research purposes. Our proprietary HEK293 expression system allows us to express difficult proteins in a human cell line to provide the most authentic recombinant products possible. The new IFN beta further expands our animal component-free HumanKine product line, and the product is priced competitively and also available in bulk.”

Glycosylation of the IFN beta protein by a single asparagine-linked sugar chain is essential to its activity and stability, both in vitro and in vivo. IFN beta purified from human cells has been shown to have the highest biologic activity and stability compared to recombinant human IFN beta produced in non-human expression systems. HumanZyme’s recombinant human IFN beta expressed in human cells assures native processing, glycosylation and folding of the purified protein compared to bacterial, mammalian cell lines, or insect cell expression systems, preserving its biologic function and activity. HumanZyme’s HumanKine proteins are also animal-derived product free, xeno-free and carrier-free.

For more information, see our Interferon beta product page.

About HumanZyme, Inc.:
HumanZyme, Inc. is the global leader in providing highly authentic recombinant human proteins from human cells. Our process is cost-effective and scalable making our proteins suitable for the research, diagnostic, drug discovery and biopharmaceutical markets. HumanZyme leverages its proprietary engineered human cells, expression vector, and cell culture media to ensure high-yield production of recombinant proteins with native human post-translational modifications. We are a leading provider of cytokines and growth factors and a preferred outsourcing supplier of human protein production. Our products and services support a broad range of customers worldwide, from academic and government research institutions to biotechnology and pharmaceutical companies.

Read the full story at http://www.prweb.com/releases/2017/08/prweb14577825.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. HumanZyme® Launches New XKine™ Recombinant Protein Line Expanding Reagents For Stem Cell Research and Regenerative Medicine Applications
2. DistinctBright, Probiotic Cleaner, Announces their Probiotic Cleaner is Safe for Pets
3. Annual Conference about Technology Solutions for People with Disabilities Announces Program
4. Probiotic Action Announces Probiotics Lead the Digestive Health Market
5. Verenium Announces Preliminary Financial Results For Fiscal 2012
6. Senomyx Announces Fourth Quarter And Full Year 2012 Financial Results And Initiation Of New Direct Sales Strategy
7. Neuralstem Announces 2012 Financial Results, Provides Clinical Trials Update
8. EAG Announces New General Manager of Release-To-Production (RTP) Division
9. DuPont Tate & Lyle Bio Products Announces Novel Application for Zemea® Propanediol
10. Probiotic Action Announces China’s $5 Billion Dollar Investment in Probiotics
11. EAS Consulting Group, Experts in Quality Regulatory Services Related to FDA Issues, Announces Upcoming Dietary Supplement Seminars in Salt Lake City
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/4/2019)... (PRWEB) , ... January 03, 2019 , ... ... the forefront of oncolytic virus-based immunotherapies for cancer, today announced the founding of ... to receive critical input and guidance from key leaders in the Immuno-Oncology field. ...
(Date:12/19/2018)... , ... December 19, 2018 , ... ... at its first rate Stem Cell Training Course in Las Vegas. Training includes ... As regenerative procedures explode in popularity nationwide for aesthetics, having the training from ...
(Date:12/18/2018)... ... December 17, 2018 , ... ABCT , the Accelerator ... invited to participate in the annual program. Twelve ventures will participate in the ... professional network. All startups receive an entrepreneur coach, access to active business professionals ...
(Date:12/18/2018)... ... 2018 , ... Patients with early stages of breast cancer who undergo partial ... whole breast irradiation, a new study suggests. , Patients with early stage breast cancer ... removal of the cancerous tumor because there is a 30 to 40 percent change ...
Breaking Biology Technology:
(Date:1/10/2019)... ... 2019 , ... Dr. Beanlands is the Vered Chair and Division Head of ... is also Director of its National Cardiac PET Centre, and Professor in the University's ... in the Department of Cellular and Molecular medicine. , He is a founding member ...
(Date:1/8/2019)... ... January 07, 2019 , ... Sonion , ... hearing instruments and specialty earphones, and Valencell , the leading innovator in ... in canal with an embedded biometric sensor. The BiometRIC measures key vital signs ...
(Date:1/4/2019)... Whitehouse, N WHITEHOUSE, N.J. (PRWEB) , ... January ... ... have begun to rapidly adopt 3D cell culture models into their drug discovery ... organoids. While these models improve the in vivo relevancy of in vitro studies, ...
Breaking Biology News(10 mins):